Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older

Journal of Infectious Diseases

Volumn 197, Issue 9, 2008, Pages 1289-1295

  Arora, Anita ^a,d   Mendoza, Natalia ^b   Brantley, Julie ^a   Yates, Barbara ^c   Dix, Lynn ^c   Tyring, Stephen ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b CENTER FOR CLINICAL STUDIES   (United States)

^c GLAXOSMITHKLINE   (United States)

^d U T Psychiatry Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VALACICLOVIR;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HEALING; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; SAFETY; VALINE;

EID: 43049094029     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/586903     Document Type: Article

References (19)

1. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
2. Wentworth BB, Alexander ER. Seroepidemiology of infections due to members of the herpesvirus group. Am J Epidemiol 1971; 94:496-507.
3. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61:310-6.
4. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Derm 1957; 75:193-6.
5. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980; 30:582-7.
6. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142:291-3.
7. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19:13-22.
8. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4:108-15.
9. Burgoon CF Jr, Burgoon JS, Baldridge GD. The natural history of herpes zoster. J Am Med Assoc 1957; 164:265-9.
10. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571-5.
11. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85:79-83.
12. Cobo M, Foulks GN, Liesegang T, et al. Observations on the natural history of herpes zoster ophthalmicus. Curr Eye Res 1987; 6:195-9.
13. Balfour HH, Jr., Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308:1448-53.
14. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314:208-12.
15. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546-53.
16. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995; 28:281-90.
17. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. New Engl J Med 1996; 335:32-42.
18. Rolston KV, Manzullo E, Elting L, Frisbee-Hume S, Rodriguez S, Rubenstein EB. Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients. Support Care Cancer 1998; 6:57-62.
19. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369-80.